Tag: point of care infectious disease testing market size

Uncover key drivers, emerging technologies, and competitive movements shaping the point of care infectious disease testing market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Point Of Care Infectious Disease Testing Market expected to grow between 2026 and 2030?

The point of care infectious disease testing market has witnessed rapid growth in recent years. It is forecast to grow from $4.78 billion in 2025 to $5.44 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.7%. This historical growth can be linked to factors such as the rising incidence of infectious diseases, an increased need for rapid diagnostics, the expansion of decentralized healthcare delivery, the availability of lateral flow testing technologies, and the growing utilization of rapid screening within hospitals.

The point of care infectious disease testing market is anticipated to experience substantial expansion over the next few years, projected to reach $9.02 billion in 2030 with a compound annual growth rate (CAGR) of 13.5%. This growth during the forecast period is attributable to the increasing embrace of self-testing solutions, the broadening scope of molecular point-of-care diagnostics, escalating investments in digital health integration, a heightened focus on outbreak preparedness, and the rising demand for low-cost rapid tests. Prominent trends for the upcoming period include the growing adoption of rapid molecular point-of-care tests, an increasing demand for home-based infectious disease testing, the expanding use of multiplex diagnostic kits, the proliferation of portable diagnostic instruments, and an intensified focus on early disease detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24382&type=smp

Which Drivers Are Influencing Market Acceleration In The Point Of Care Infectious Disease Testing Market?

The anticipated expansion of the point of care infectious disease testing market is driven by the increasing prevalence of contagious diseases. Such diseases are defined as illnesses transferable among individuals via direct contact, airborne particles, or alternative transmission methods. The primary reason for this increase in contagious disease cases is heightened human mobility, which enables infectious agents to spread more rapidly and extensively across regions and nations. Point of care infectious disease testing plays a crucial role by expediting the detection and diagnosis of these diseases, thereby facilitating prompt treatment and mitigating community transmission risks. As an illustration, in June 2024, data from the UK Health Security Agency, a UK-based government agency, revealed that from week 40 of 2022 to week 15 of 2023, 108 NHS trusts in England reported 1,681 critical care admissions attributed to confirmed influenza. This figure stands in stark contrast to the prior flu season, which saw only 182 admissions across 114 trusts, a number that subsequently rose to 316 by week 39 of 2022. Consequently, the escalating number of contagious diseases is a significant factor propelling the expansion of the point of care infectious disease testing market.

What Segments Are Identified Within The Structure Of The Point Of Care Infectious Disease Testing Market?

The point of care infectious disease testing market covered in this report is segmented –

1) By Product: Kits And Reagents, Instruments

2) By Technology: Lateral Flow Immunoassay, Agglutination Test, Flow-through Test Or Immunoconcentration Assay, Molecular Diagnostics, Other Technologies

3) By Disease: Human Immunodeficiency Virus Point-of-Care Testing, Clostridium Difficile Point-of-Care Testing, Hepatitis B Virus Point-of-Care Testing, Pneumonia or Streptococcus Associated Infections, Respiratory Syncytial Virus Point-of-Care Testing, Human Papillomavirus Point-of-Care Testing, Influenza Or Flu Point-of-Care Testing, Other Diseases

4) By End Use: Hospitals, Diagnostic Centers, Research and Academic Institutes, Homecare Settings, Other End Users

Subsegments:

1) By Kits And Reagents: Test Kits, Reagents

2) By Instruments: Portable Devices, Automated Analyzers

What Industry Trends Are Transforming The Point Of Care Infectious Disease Testing Market?

Leading firms within the point-of-care infectious disease testing market are prioritizing the incorporation of cutting-edge innovations, such as proprietary microfluidic technology, aiming to boost precision in testing, shorten result delivery times, and better patient health outcomes. This specialized microfluidic technology involves advanced systems capable of handling minute fluid volumes at a microscopic level, facilitating quick, accurate, and economical analysis. Its utility in point of care (POC) infectious disease testing stems from its capacity for swift, on-site pathogen identification, combining sample gathering, analysis, and result generation, thus accelerating diagnostics and broadening access without relying on central laboratory facilities. For instance, in June 2023, Sysmex Corporation, a Japan-based diagnostics company, launched the PA-100 AST System in Europe, which represents the globe’s inaugural point-of-care testing product designed for direct antimicrobial susceptibility detection. Leveraging sophisticated microfluidic techniques, this system facilitates quick identification of bacterial pathogens and assesses the efficacy of antimicrobials, thereby substantially cutting down on processing duration when juxtaposed with traditional approaches. The setup includes a small, desktop-sized analyzer along with disposable sample cartridges, rendering it ideal for use in close-to-patient environments like primary care clinics. Intended to aid in quicker and more precise decisions regarding antimicrobial therapy, this system supports worldwide initiatives to counteract antimicrobial resistance through enhanced diagnostic effectiveness.

Which Major Firms Are Strengthening Their Position In The Point Of Care Infectious Disease Testing Market?

Major companies operating in the point of care infectious disease testing market are Cardinal Health, F Hoffmann La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company, bioMérieux Société Anonyme, QuidelOrtho Corporation, Bio Rad Laboratories Inc., DiaSorin Società per Azioni, Danaher Corporation, Cue Health Inc., Nova Biomedical Corporation, Seegene Incorporated, Biosynex Société Anonyme, Trivitron Healthcare Private Limited, EKF Diagnostics Holdings plc, Trinity Biotech Public Limited Company, bioLytical Laboratories Inc., Cepheid Inc., LumiraDx UK Ltd., Meridian Bioscience Inc., GenBody Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/point-of-care-infectious-disease-testing-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Point Of Care Infectious Disease Testing Market?

North America was the largest region in the point of care infectious disease testing market in 2025. Asia-Pacific is expected to be the Fastest-Growing region in the forecast period. The regions covered in the point of care infectious disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Point Of Care Infectious Disease Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24382&type=smp

Browse Through More Reports Similar to the Global Point Of Care Infectious Disease Testing Market 2026, By The Business Research Company

Point Of Care Poc Coagulation Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-poc-coagulation-testing-global-market-report

Point Of Care Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-global-market-report

Hospital Acquired Infections Testing Kits Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the point of care infectious disease testing market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Point Of Care Infectious Disease Testing Market expected to grow between 2026 and 2030?

The point of care infectious disease testing market has witnessed rapid growth in recent years. It is forecast to grow from $4.78 billion in 2025 to $5.44 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.7%. This historical growth can be linked to factors such as the rising incidence of infectious diseases, an increased need for rapid diagnostics, the expansion of decentralized healthcare delivery, the availability of lateral flow testing technologies, and the growing utilization of rapid screening within hospitals.

The point of care infectious disease testing market is anticipated to experience substantial expansion over the next few years, projected to reach $9.02 billion in 2030 with a compound annual growth rate (CAGR) of 13.5%. This growth during the forecast period is attributable to the increasing embrace of self-testing solutions, the broadening scope of molecular point-of-care diagnostics, escalating investments in digital health integration, a heightened focus on outbreak preparedness, and the rising demand for low-cost rapid tests. Prominent trends for the upcoming period include the growing adoption of rapid molecular point-of-care tests, an increasing demand for home-based infectious disease testing, the expanding use of multiplex diagnostic kits, the proliferation of portable diagnostic instruments, and an intensified focus on early disease detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24382&type=smp

Which Drivers Are Influencing Market Acceleration In The Point Of Care Infectious Disease Testing Market?

The anticipated expansion of the point of care infectious disease testing market is driven by the increasing prevalence of contagious diseases. Such diseases are defined as illnesses transferable among individuals via direct contact, airborne particles, or alternative transmission methods. The primary reason for this increase in contagious disease cases is heightened human mobility, which enables infectious agents to spread more rapidly and extensively across regions and nations. Point of care infectious disease testing plays a crucial role by expediting the detection and diagnosis of these diseases, thereby facilitating prompt treatment and mitigating community transmission risks. As an illustration, in June 2024, data from the UK Health Security Agency, a UK-based government agency, revealed that from week 40 of 2022 to week 15 of 2023, 108 NHS trusts in England reported 1,681 critical care admissions attributed to confirmed influenza. This figure stands in stark contrast to the prior flu season, which saw only 182 admissions across 114 trusts, a number that subsequently rose to 316 by week 39 of 2022. Consequently, the escalating number of contagious diseases is a significant factor propelling the expansion of the point of care infectious disease testing market.

What Segments Are Identified Within The Structure Of The Point Of Care Infectious Disease Testing Market?

The point of care infectious disease testing market covered in this report is segmented –

1) By Product: Kits And Reagents, Instruments

2) By Technology: Lateral Flow Immunoassay, Agglutination Test, Flow-through Test Or Immunoconcentration Assay, Molecular Diagnostics, Other Technologies

3) By Disease: Human Immunodeficiency Virus Point-of-Care Testing, Clostridium Difficile Point-of-Care Testing, Hepatitis B Virus Point-of-Care Testing, Pneumonia or Streptococcus Associated Infections, Respiratory Syncytial Virus Point-of-Care Testing, Human Papillomavirus Point-of-Care Testing, Influenza Or Flu Point-of-Care Testing, Other Diseases

4) By End Use: Hospitals, Diagnostic Centers, Research and Academic Institutes, Homecare Settings, Other End Users

Subsegments:

1) By Kits And Reagents: Test Kits, Reagents

2) By Instruments: Portable Devices, Automated Analyzers

What Industry Trends Are Transforming The Point Of Care Infectious Disease Testing Market?

Leading firms within the point-of-care infectious disease testing market are prioritizing the incorporation of cutting-edge innovations, such as proprietary microfluidic technology, aiming to boost precision in testing, shorten result delivery times, and better patient health outcomes. This specialized microfluidic technology involves advanced systems capable of handling minute fluid volumes at a microscopic level, facilitating quick, accurate, and economical analysis. Its utility in point of care (POC) infectious disease testing stems from its capacity for swift, on-site pathogen identification, combining sample gathering, analysis, and result generation, thus accelerating diagnostics and broadening access without relying on central laboratory facilities. For instance, in June 2023, Sysmex Corporation, a Japan-based diagnostics company, launched the PA-100 AST System in Europe, which represents the globe’s inaugural point-of-care testing product designed for direct antimicrobial susceptibility detection. Leveraging sophisticated microfluidic techniques, this system facilitates quick identification of bacterial pathogens and assesses the efficacy of antimicrobials, thereby substantially cutting down on processing duration when juxtaposed with traditional approaches. The setup includes a small, desktop-sized analyzer along with disposable sample cartridges, rendering it ideal for use in close-to-patient environments like primary care clinics. Intended to aid in quicker and more precise decisions regarding antimicrobial therapy, this system supports worldwide initiatives to counteract antimicrobial resistance through enhanced diagnostic effectiveness.

Which Major Firms Are Strengthening Their Position In The Point Of Care Infectious Disease Testing Market?

Major companies operating in the point of care infectious disease testing market are Cardinal Health, F Hoffmann La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company, bioMérieux Société Anonyme, QuidelOrtho Corporation, Bio Rad Laboratories Inc., DiaSorin Società per Azioni, Danaher Corporation, Cue Health Inc., Nova Biomedical Corporation, Seegene Incorporated, Biosynex Société Anonyme, Trivitron Healthcare Private Limited, EKF Diagnostics Holdings plc, Trinity Biotech Public Limited Company, bioLytical Laboratories Inc., Cepheid Inc., LumiraDx UK Ltd., Meridian Bioscience Inc., GenBody Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/point-of-care-infectious-disease-testing-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Point Of Care Infectious Disease Testing Market?

North America was the largest region in the point of care infectious disease testing market in 2025. Asia-Pacific is expected to be the Fastest-Growing region in the forecast period. The regions covered in the point of care infectious disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Point Of Care Infectious Disease Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24382&type=smp

Browse Through More Reports Similar to the Global Point Of Care Infectious Disease Testing Market 2026, By The Business Research Company

Point Of Care Poc Coagulation Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-poc-coagulation-testing-global-market-report

Point Of Care Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-global-market-report

Hospital Acquired Infections Testing Kits Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Point Of Care Infectious Disease Testing Market?

The market size for point of care infectious disease testing has witnessed exponential growth in recent years. It is predicted to escalate from $4.21 billion in 2024 to $4.78 billion in 2025, representing a compound annual growth rate (CAGR) of 13.6%. Factors contributing to such historic growth include the growing need for rapid diagnostic procedures, the increasing occurrence of infectious diseases, enhanced healthcare awareness, increased healthcare spending, and the rise of home care and self-testing solutions.

In the upcoming years, the market size for point of care infectious disease testing is expected to experience notable growth. By 2029, it is projected to reach $7.96 billion, with a compound annual growth rate (CAGR) of 13.6%. Several factors contributing to this growth in the forecast period include increased demand for swift diagnostics, a rise in the occurrence of infectious diseases, greater usage in remote and resources-restricted environments, a transition towards decentralized healthcare, and aid from government initiatives and funding. Top trends during the forecast period encompass progress in molecular diagnostics, improved point of care testing apparatus, innovations in biosensors and detection techniques, advancements in mobile health applications, and inventive collaborations between health service providers and technology firms.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24382&type=smp

What Drivers Are Accelerating Expansion Of The Point Of Care Infectious Disease Testing Market?

The burgeoning spread of infectious diseases is anticipated to fuel the expansion of the point of care infectious disease testing market. Contagious diseases, those communicable from person to person through direct contact, airborne droplets, or other transmission means, seem to be increasing due to enhanced human mobility. This movement across regions and countries accelerates the distribution of infectious agents. Testing infectious diseases at their point of care fast tracks detection and diagnosis, leading to early treatments and minimizing community spread. As an example, the UK Health Security Agency reported in June 2024 that 1,681 critical care admissions due to confirmed influenza between week 40 of 2022 and week 15 of 2023 occurred in 108 NHS trusts in England. This was a significant rise from the previous flu season which saw just 182 admissions across 114 trusts, a figure that increased to 316 by week 39 of 2022. As a result, the increasing spread of infectious diseases is pushing the growth of the point of care infectious disease testing market.

What Are The Primary Segmentation Parameters In The Point Of Care Infectious Disease Testing Market?

The point of care infectious disease testingmarket covered in this report is segmented –

1) By Product: Kits And Reagents; Instruments

2) By Technology: Lateral Flow Immunoassay; Agglutination Test; Flow-through Test Or Immunoconcentration Assay; Molecular Diagnostics; Other Technologies

3) By Disease: Human Immunodeficiency Virus Point-of-Care Testing; Clostridium Difficile Point-of-Care Testing; Hepatitis B Virus Point-of-Care Testing; Pneumonia or Streptococcus Associated Infections; Respiratory Syncytial Virus Point-of-Care Testing; Human Papillomavirus Point-of-Care Testing; Influenza Or Flu Point-of-Care Testing; Other Diseases

4) By End Use: Hospitals; Diagnostic Centers; Research and Academic Institutes; Homecare Settings; Other End Users

Subsegments:

1) By Kits And Reagents: Test Kits; Reagents

2) By Instruments: Portable Devices; Automated Analyzers

How Are Industry Trends Steering The Expansion Of The Point Of Care Infectious Disease Testing Market?

Leading businesses in the point-of-care infectious disease testing market are prioritizing the integration of cutting-edge technologies, including proprietary microfluidic technology. This technology is geared towards enhancing the accuracy of tests, minimizing the time to return results, and boosting patient outcomes. Proprietary microfluidic technology pertains to specialized systems that handle small fluid volumes at the microscale, enabling swift, accurate, and affordable analysis. This technology aids point-of-care (POC) infectious disease testing through immediate, on-site pathogen detection, which integrates sample collection, analysis, and result delivery, thereby accelerating diagnosis and accessibility without requiring centralized lab testing. For example, Sysmex Corporation, a diagnostics firm from Japan, in June 2023, introduced the PA-100 AST System in Europe, marking the first global point-of-care testing solution for direct detection of antimicrobial susceptibility. With the deployment of advanced microfluidic technology, this system is capable of quickly identifying bacterial infections and assessing the effectiveness of antimicrobials, greatly diminishing processing time compared to traditional procedures. The system, which is compact and desktop-sized with single-use sample cartridges, is apt for near-patient settings like primary care clinics. The system aids in making swifter and more accurate decisions concerning antimicrobial treatment, thereby boosting diagnostic efficiency and contributing to the worldwide fight against antimicrobial resistance.

Which Players Are Shaping The Competitive Landscape Of The Point Of Care Infectious Disease Testing Market?

Major companies operating in the point of care infectious disease testing market are Cardinal Health, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company, Quest Diagnostics Incorporated, bioMérieux Société Anonyme, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., DiaSorin Società per Azioni, Danaher Corporation, Cue Health Inc., Nova Biomedical Corporation, Seegene Incorporated, Biosynex Société Anonyme, Trivitron Healthcare Private Limited, EKF Diagnostics Holdings plc, Trinity Biotech Public Limited Company, bioLytical Laboratories Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/point-of-care-infectious-disease-testing-global-market-report

What Are The Emerging Regional Trends Driving The Point Of Care Infectious Disease Testing Market?

North America was the largest region in the point of care infectious disease testing market in 2024. Asia-Pacific is expected to be the Fastest-Growing region in the forecast period. The regions covered in the point of care infectious disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24382&type=smp

Browse Through More Reports Similar to the Global Point Of Care Infectious Disease Testing Market 2025, By The Business Research Company

Veterinary Point Of Care Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-point-of-care-diagnostics-global-market-report

Point Of Care Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-global-market-report

Point Of Care Ultrasound Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/point-of-care-ultrasound-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Point Of Care Infectious Disease Testing Market By 2029?

The point of care infectious disease testing market has experienced significant expansion in recent years. It is projected to increase from $4.21 billion in 2024 to $4.78 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.6%. Historically, this growth can be attributed to a heightened demand for swift diagnostic methods, a growing prevalence of infectious diseases, increased awareness regarding healthcare, greater healthcare spending, and an uptick in the use of home care and self-testing options.

The point of care infectious disease testing market size is anticipated to undergo swift expansion in the coming years. It is projected to achieve $7.96 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 13.6%. This projected growth throughout the forecast period stems from factors such as increasing demand for rapid diagnostic tools, the rising prevalence of infectious diseases, wider adoption in remote and resource-constrained environments, a move towards decentralized healthcare, and favorable government initiatives and funding. Significant trends expected during this forecast period involve advancements in molecular diagnostics, enhanced point of care testing devices, innovation in biosensors and detection technologies, progress in mobile health applications, and new partnerships between healthcare providers and technology companies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24382&type=smp

Which Major Market Drivers Are Shaping The Future Of The Point Of Care Infectious Disease Testing Market?

The increasing prevalence of contagious diseases is anticipated to fuel the expansion of the point of care infectious disease testing market moving ahead. Contagious diseases are defined as illnesses capable of spreading between individuals via direct contact, airborne particles, or alternative transmission methods. The increasing occurrence of these diseases is primarily attributed to heightened human movement, where increased travel across regions and countries enables quicker and broader dissemination of infectious agents. Point of care infectious disease testing speeds up the identification and diagnosis of contagious illnesses, allowing for prompt medical intervention and lowering the chance of spread within populations. For example, in June 2024, data from the UK Health Security Agency, a UK-based government agency, showed that from week 40 of 2022 to week 15 of 2023, 108 NHS trusts in England documented 1,681 critical care admissions attributed to confirmed influenza. This was a substantial increase compared to the previous flu season, which recorded only 182 admissions across 114 trusts, a number that had risen to 316 by week 39 of 2022. Consequently, the surge in contagious diseases is propelling the expansion of the point of care infectious disease testing market.

How Is The Point Of Care Infectious Disease Testing Market Segmented?

The point of care infectious disease testingmarket covered in this report is segmented –

1) By Product: Kits And Reagents; Instruments

2) By Technology: Lateral Flow Immunoassay; Agglutination Test; Flow-through Test Or Immunoconcentration Assay; Molecular Diagnostics; Other Technologies

3) By Disease: Human Immunodeficiency Virus Point-of-Care Testing; Clostridium Difficile Point-of-Care Testing; Hepatitis B Virus Point-of-Care Testing; Pneumonia or Streptococcus Associated Infections; Respiratory Syncytial Virus Point-of-Care Testing; Human Papillomavirus Point-of-Care Testing; Influenza Or Flu Point-of-Care Testing; Other Diseases

4) By End Use: Hospitals; Diagnostic Centers; Research and Academic Institutes; Homecare Settings; Other End Users

Subsegments:

1) By Kits And Reagents: Test Kits; Reagents

2) By Instruments: Portable Devices; Automated Analyzers

What Trends Are Expected To Drive The Point Of Care Infectious Disease Testing Market?

Major companies in the point-of-care infectious disease testing market are concentrating on integrating innovative technologies, such as proprietary microfluidic technology, to improve test accuracy, reduce the time needed for results, and enhance patient outcomes. Proprietary microfluidic technology refers to specialized systems designed to manipulate small volumes of fluids at the microscale, which enables rapid, precise, and cost-effective analysis. This greatly benefits point of care (POC) infectious disease testing by allowing immediate, on-site pathogen detection, including integrated sample collection, analysis, and result output, thereby accelerating diagnostic speed and accessibility without requiring centralized laboratory testing. For instance, in June 2023, Sysmex Corporation, a Japan-based diagnostics company, launched the PA-100 AST System in Europe, introducing the world’s first point-of-care testing solution for directly identifying antimicrobial susceptibility. Utilizing advanced microfluidic technology, this system facilitates quick identification of bacterial infections and evaluation of antimicrobial effectiveness, substantially reducing processing time compared to conventional methods. It includes a compact, desktop-sized analyzer and single-use sample cartridges, making it ideal for near-patient settings like primary care clinics. Designed to enable faster and more accurate antimicrobial therapy decisions, the system contributes to the global fight against antimicrobial resistance by enhancing diagnostic efficiency.

Which Major Industry Participants Are Leading The Point Of Care Infectious Disease Testing Market Growth?

Major companies operating in the point of care infectious disease testing market are Cardinal Health, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company, Quest Diagnostics Incorporated, bioMérieux Société Anonyme, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., DiaSorin Società per Azioni, Danaher Corporation, Cue Health Inc., Nova Biomedical Corporation, Seegene Incorporated, Biosynex Société Anonyme, Trivitron Healthcare Private Limited, EKF Diagnostics Holdings plc, Trinity Biotech Public Limited Company, bioLytical Laboratories Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/point-of-care-infectious-disease-testing-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Point Of Care Infectious Disease Testing Market?

North America was the largest region in the point of care infectious disease testing market in 2024. Asia-Pacific is expected to be the Fastest-Growing region in the forecast period. The regions covered in the point of care infectious disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Point Of Care Infectious Disease Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24382&type=smp

Browse Through More Reports Similar to the Global Point Of Care Infectious Disease Testing Market 2025, By The Business Research Company

Veterinary Point Of Care Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-point-of-care-diagnostics-global-market-report

Point Of Care Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-global-market-report

Point Of Care Ultrasound Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/point-of-care-ultrasound-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Point Of Care Infectious Disease Testing Market Size From 2025 to 2034?

In recent times, the market size for point of care infectious disease testing has seen notable growth. The market, which is expected to expand from $4.21 billion in 2024 to $4.78 billion, will do so with a compound annual growth rate (CAGR) of 13.6% in 2025. Fueling this historical growth period is the rising demand for swift diagnostic services, the increasing occurrence of infectious diseases, heightened healthcare consciousness, growing healthcare expenses and the upswing in the usage of home care and self-testing options.

Anticipations are high for a swift expansion of the point of care infectious disease testing market in the years to come, with estimations suggesting a rise to$7.96 billion in 2029 showcasing a compound annual growth rate (CAGR) of 13.6%. This projected growth within the stipulated period can be associated with factors such as the upsurge in the need for swift diagnosis, higher occurrences of infectious diseases, increased utilization in remote and resource-deficient areas, a transition towards more localized healthcare, and the introduction of favourable government schemes and funding. Key trends expected during this forecast window encompass progress in molecular diagnostics, improved point of care testing gadgets, evolution in biosensors and detection techniques, strides in mobile health applications, and inventive collaborations between healthcare practitioners and technology organizations.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24382&type=smp

What Are the Core Growth Drivers Propelling the Point Of Care Infectious Disease Testing Market Forward?

The expanding influence of communicable diseases is anticipated to drive the expansion of the point of care infectious disease testing market. Communicable diseases, those that can be transferred from person to person in various ways including direct contact and airborne droplets, are on the rise due to increased human mobility. As people traverse different regions and nations more freely, the spread of infectious agents becomes quicker and broader. Point of care testing for infectious diseases speeds up the identification and diagnosis of these diseases, allowing for prompt treatment and minimising further spread within populations. As an example, the UK Health Security Agency reported in June 2024 that between week 40 of 2022 and week 15 of 2023, 108 NHS trusts in England counted 1,681 critical care admissions owing to confirmed cases of influenza. This compares to just 182 admissions across 114 trusts in the prior flu season, which had risen to 316 by week 39 of 2022. As a result, the growing incidence of communicable diseases is fueling the expansion of the point of care infectious disease testing market.

What Segment Types Define the Point Of Care Infectious Disease Testing Market Structure?

The point of care infectious disease testingmarket covered in this report is segmented –

1) By Product: Kits And Reagents; Instruments

2) By Technology: Lateral Flow Immunoassay; Agglutination Test; Flow-through Test Or Immunoconcentration Assay; Molecular Diagnostics; Other Technologies

3) By Disease: Human Immunodeficiency Virus Point-of-Care Testing; Clostridium Difficile Point-of-Care Testing; Hepatitis B Virus Point-of-Care Testing; Pneumonia or Streptococcus Associated Infections; Respiratory Syncytial Virus Point-of-Care Testing; Human Papillomavirus Point-of-Care Testing; Influenza Or Flu Point-of-Care Testing; Other Diseases

4) By End Use: Hospitals; Diagnostic Centers; Research and Academic Institutes; Homecare Settings; Other End Users

Subsegments:

1) By Kits And Reagents: Test Kits; Reagents

2) By Instruments: Portable Devices; Automated Analyzers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24382&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Point Of Care Infectious Disease Testing Market?

North America was the largest region in the point of care infectious disease testing market in 2024. Asia-Pacific is expected to be the Fastest-Growing region in the forecast period. The regions covered in the point of care infectious disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing thePoint Of Care Infectious Disease Testing Industry Evolution?

Leading businesses in the point-of-care infectious disease testing market are concentrating on incorporating groundbreaking technologies like proprietary microfluidic technology. This takes the testing accuracy, swiftness of results, and patient outcomes up a notch. Proprietary microfluidic technology involves distinct systems that handle tiny fluid amounts on a microscopic scale. This allows for a quick, exact, and affordable analysis that benefits point of care (POC) infectious disease testing. It does this by making possible speedy pathogen identification on-site with integrated sample collection, scrutiny, and results, thereby increasing speed and accessibility of diagnoses without requiring centralized lab testing. For example, in June 2023, Sysmex Corporation, a diagnostics firm from Japan, launched the PA-100 AST System in Europe, marking the first global point-of-care testing solution for immediate antimicrobial susceptibility detection. Through the utilization of revolutionary microfluidic technology, the system expedites the identification of bacterial infections and the evaluation of antimicrobial effectiveness. This slashes the processing time in comparison to traditional methods. It comprises a compact, desktop-sized analyzer and single-use sample cartridges, rendering it suitable for near-patient environments like primary care clinics. Developed to aid swifter and more precise antimicrobial therapy determinations, the system aids the worldwide initiative to defeat antimicrobial resistance by boosting diagnostic effectiveness.

View the full report here:

https://www.thebusinessresearchcompany.com/report/point-of-care-infectious-disease-testing-global-market-report

What Is the Definition of the Point Of Care Infectious Disease Testing Market?

Point of care (POC) infectious disease testing refers to diagnostic tests that are performed at or near the site of patient care, such as hospitals, clinics, doctors’ offices, or even at home. These tests are designed to detect infectious diseases quickly and accurately, providing immediate results to facilitate prompt treatment decisions. POC tests are typically user-friendly, require minimal equipment, and offer results within minutes to hours, making them ideal for situations where timely diagnosis is crucial.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24382

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Are the Key Projections for the CAGR of the Point Of Care Infectious Disease Testing Market Size From 2025 to 2034?

The market size for point of care infectious disease testing has been expanding rapidly in the recent years. It is predicted to surge from $4.21 billion in 2024 to $4.79 billion in 2025, registering a compound annual growth rate (CAGR) of 14.0%. Factors contributing to the growth observed in the historic period include a surge in demand for fast diagnostic solutions, increasing prevalence of infectious diseases, growing health consciousness, escalation in healthcare spending, and a rise in the adoption rate of home care and self-testing solutions.

The market size for point of care infectious disease testing is predicted to experience swift expansion in the upcoming years, mushrooming to $8.02 billion in 2029. The compound annual growth rate (CAGR) stands at 13.7%. Factors contributing to such growth during this projection period include the soaring demand for rapid diagnostic techniques, an increase in the cases of infectious diseases, wider adoption in isolated and resource-constrained environments, a transition towards localized healthcare, and the positive role of government initiatives and funding. The impending period also exhibits major advancements in molecular diagnostics, state-of-the-art point of care testing equipment, innovations in biosensors and detection methodologies, development in mobile health applications, and creative alliances between healthcare professionals and technology firms.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24382&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Point Of Care Infectious Disease Testing Market?

Expectations are that the escalating prevalence of contagious diseases will boost the expansion of the point of care infectious disease testing market. Contagious illnesses are diseases that can be transmitted from one individual to another through direct touch, aerosols in the air, or other transmission methods. The surge in such illnesses is largely due to the increase in human mobility since a higher frequency of people traveling between regions and countries enables the quicker and broader spread of infectious agents. Point of care testing for infectious diseases hastens the identification and diagnosis of such illnesses, facilitating prompt treatment and diminishing the likelihood of transmission within communities. For instance, as per data from the UK Health Security Agency, a governmental organization in the UK, from the 40th week of 2022 to the 15th week of 2023, 108 NHS trusts in England documented 1,681 critical care admissions due to verified cases of influenza. In contrast, the previous influenza season saw only 182 admissions across 114 trusts, which rose to 316 by the 39th week of 2022. Hence, it’s evident that the surge in contagious illnesses is fueling the growth of the point of care infectious disease testing market.

Which Key Market Segments Comprise the Point Of Care Infectious Disease Testing Market and Drive Its Revenue Growth?

The point of care infectious disease testing market covered in this report is segmented –

1) By Product: Kits And Reagents, Instruments

2) By Technology: Lateral Flow Immunoassay, Agglutination Test, Flow-through Test Or Immunoconcentration Assay, Molecular Diagnostics, Other Technologies

3) By Disease: Human Immunodeficiency Virus Point-of-Care Testing, Clostridium Difficile Point-of-Care Testing, Hepatitis B Virus Point-of-Care Testing, Pneumonia or Streptococcus Associated Infections, Respiratory Syncytial Virus Point-of-Care Testing, Human Papillomavirus Point-of-Care Testing, Influenza Or Flu Point-of-Care Testing, Other Diseases

4) By End Use: Hospitals, Diagnostic Centers, Research and Academic Institutes, Homecare Settings, Other End Users

Subsegments:

1) By Kits And Reagents: Test Kits, Reagents

2) By Instruments: Portable Devices, Automated Analyzers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24382&type=smp

Which Areas Are Leading Regions in the Point Of Care Infectious Disease Testing Market Expansion Across the Globe?

North America was the largest region in the point of care infectious disease testing market in 2024. Asia-Pacific is expected to be the Fastest-Growing region in the forecast period. The regions covered in the point of care infectious disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in the Point Of Care Infectious Disease Testing Market Over the Coming Years?

Significant players in the point-of-care infectious disease testing market are concentrating on incorporating ground-breaking technologies like proprietary microfluidic technology to augment test precision, decrease time-to-outcomes, and uplift patient results. Proprietary microfluidic technology is a technique handling tiny volumes of fluids at the microscale, leading to swift, accurate, and economical diagnostic analysis, favouring point of care (POC) infectious disease testing. This technology simplifies on-the-spot, speedy detection of pathogens with amalgamated sample gathering, examination, and result generation, thus enhancing the pace and availability of diagnostics by eliminating the need for centralized laboratory tests. As an illustration, the Sysmex Corporation, which is a diagnostic company based in Japan, released the PA-100 AST System in Europe in June 2023, debuting as the world’s first solution for point-of-care testing that accurately detects antimicrobial susceptibility. With the use of advanced microfluidic technology, the system expedites identification of bacterial infections and assessment of antimicrobial effectiveness, which considerably diminishes processing time in comparison to traditional techniques. The system boasts a concise, desktop-sized analyzer and cartridges for single-use sample collection, making it ideal for near-patient environments like primary care clinics. The system is engineered to enable faster and precise decisions on antimicrobial therapy and contributes to global initiatives to tackle antimicrobial resistance by enhancing diagnostic productivity.

View the full report here:

https://www.thebusinessresearchcompany.com/report/point-of-care-infectious-disease-testing-global-market-report

How Is the Point Of Care Infectious Disease Testing Market Conceptually Defined?

Point of care (POC) infectious disease testing refers to diagnostic tests that are performed at or near the site of patient care, such as hospitals, clinics, doctors’ offices, or even at home. These tests are designed to detect infectious diseases quickly and accurately, providing immediate results to facilitate prompt treatment decisions. POC tests are typically user-friendly, require minimal equipment, and offer results within minutes to hours, making them ideal for situations where timely diagnosis is crucial.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/customise?id=24382&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model